CAS 875165-39-2

Fórmula: C19H14BrClN4O2S

InChI: InChI=1S/C19H14BrClN4O2S/c20-13-5-1-11(2-6-13)9-16-22-23-19-25(16)24-18(15(28-19)10-17(26)27)12-3-7-14(21)8-4-12/h1-8,15H,9-10H2,(H,26,27)

Chave InChI: BWGPJTANFXCCTH-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1CC2=NN=C3N2N=C(C(S3)CC(=O)O)C4=CC=C(C=C4)Cl)Br

2-(3-(4-Bromobenzyl)-6-(4-chlorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-7-yl)acetic acid

CAS: 875165-39-2

2-(3-(4-Bromobenzyl)-6-(4-chlorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-7-yl)acetic acid

Fórmula: C₁₉H₁₄BrClN₄O₂S

Pureza: 98%

Peso molecular: 477.77

Ref: 54-OR1067758

TCL-1

CAS: 875165-39-2

2-(3-(4-Bromobenzyl)-6-(4-chlorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-7-yl)acetic acid

Fórmula: C₁₉H₁₄BrClN₄O₂S

Pureza: 98%

Peso molecular: 477.76

Ref: IN-DG01225872

TCL1

CAS: 875165-39-2

TCL1 acts as a selective non-covalent inhibitor targeting the Pru domain of the Rpn-13 subunit within the 19S regulatory particle (19S RP) of the proteasome, with an IC50 value around 26 μM. It disrupts the recognition and transport of ubiquitinated proteins by Rpn-13, thus inhibiting proteasomal degradation and affecting intracellular protein metabolism balance. TCL1 holds potential for research in hematologic malignancies.

Fórmula: C₁₉H₁₄BrClN₄O₂S

Cor e Forma: Solid

Peso molecular: 477.762

Ref: TM-T206909